Abstract 46P
Background
ABCB1 gene reported to affect chemo-induced toxicity through drug disposition and efflux mechanisms. This study aims to evaluate the influence of ABCB1 (C1236T, G2677T/A, C3435T) polymorphisms on, chemotoxicity, and survival outcomes in BC patients treated with anthracycline and taxane either sequentially or concomitantly.
Methods
100 patients were included who received sequential or concomitant anthracycline and taxane as per clinician discretion and underwent modified radical mastectomy. Chemotoxicity grade was analyzed by CTCAE v.4. All patients received standard premedication with 5HT3, NK1 receptor antagonist, dexamethasone, H2 blocker/ PPI. SNP of ABCB1 (C1236T, G2677T/A, C3435T) gene was detected by PCR-RFLP and sequencing.
Results
Patients mostly reported at Stage III (52.89%) with infiltrating ductal carcinoma subtype (90.9%) who received sequential (50%) & concomitant (50%) chemotherapy. Grade ≥2 chemo toxicity like neutropenic fever, significantly associated with C1236T SNP with odd ratio (OR) for TT genotypes was 2.00 (95% CI: 0.125-31.975, p=0.000), while in CT genotypes, it stood at 1.100 (95% CI: 0.063-15.988; p = 0.035). Meanwhile, vomiting was significantly associated with C3435T for TT genotypes, with an OR of 3.031 (95% CI: 0.031-7.994, p=0.05). TT genotypes (C1236T) were significantly associated with nausea (OR: 2.667; 95% CI: 1.043-6.815; p = 0.04). Alopecia was observed 88% patients. However, ABCB1 showed no significant (p = 0.416, Log-rank) correlation for overall survival. Although, no significant associations were found for G2677T/A in terms of toxicity and survival.
Conclusions
The homozygous mutant TT genotypes (C1236T and C3435T) and heterozygous CT genotypes (C1236T) showed significant association to chemo-induced toxicity (hematological toxicity, nausea, vomiting, alopecia) in patients underwent anthracycline and taxane. Hence, these SNPs could serve as predictive markers to mitigate chemotherapy's adverse effects and optimize treatment to reduce the grade of toxicity and improves patients quality of life.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
V. D. Nasare.
Funding
This work is funded by Council of Scientific and Industrial Research, Government of India, File No. 09/030(0085)/2019-EMR-I awarded to Tanuma Mistry.
Disclosure
The author has declared no conflicts of interest.
Resources from the same session
442P - Negative impact on bone homeostasis in postmenopausal women with non-metastatic breast cancer during cytotoxic chemotherapy
Presenter: Yadav Nisha
Session: Poster Display
Resources:
Abstract
443P - Efficacy of vitamin D supplementation in overall survival of cancer patients: Systematic review and meta-analysis
Presenter: Visakha Irawan
Session: Poster Display
Resources:
Abstract
444P - Commencing a nurse led symptom and urgent review clinic (SURC) in a Victorian regional cancer centre
Presenter: Sue Bartlett
Session: Poster Display
Resources:
Abstract
445P - Self-reported symptom burden, quality of life and unmet need of symptom management in nasopharyngeal cancer survivors: A cross-sectional survey
Presenter: Jerry Ching
Session: Poster Display
Resources:
Abstract
446P - A single center experience of anamorelin in patients with non-small cell lung cancer
Presenter: Takanori Ito
Session: Poster Display
Resources:
Abstract
447P - Quality of life in patients with EGFR-mutated lung cancer receiving gefitinib vs gefitinib plus pemetrexed and carboplatin chemotherapy
Presenter: Nandini Menon
Session: Poster Display
Resources:
Abstract
448P - Association of clinicopathological characteristics and pro-inflammatory markers with reduced relative dose intensity in breast cancer chemotherapy
Presenter: Susanna Hutajulu
Session: Poster Display
Resources:
Abstract
449P - Psychometric validation of the MD Anderson symptom inventory head&neck module: Chinese version in nasopharyngeal cancer survivors
Presenter: Victor Tam
Session: Poster Display
Resources:
Abstract
450P - Retrospective study of anamorelin therapy for unresectable or recurrent pancreatic cancer with cancer cachexia
Presenter: Mao Okada
Session: Poster Display
Resources:
Abstract
451P - The real-world efficacy and safety of anamorelin hydrochloride for Japanese unresectable non-small cell lung cancer patients with cachexia
Presenter: Daisuke Arai
Session: Poster Display
Resources:
Abstract